Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

MRK
Merck & Co., Inc.
stock NYSE

At Close
Oct 13, 2025 3:59:56 PM EDT
85.64USD-0.453%(-0.39)6,524,767
0.00Bid   0.00Ask   0.00Spread
Pre-market
Oct 13, 2025 9:26:30 AM EDT
85.79USD-0.279%(-0.24)13,816
After-hours
Oct 13, 2025 4:57:30 PM EDT
85.73USD+0.105%(+0.09)80,749
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsDividendsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
09:49AM EST  Price To Earnings Ratio Insights For Merck & Co   Benzinga
Jan 28, 2022
02:03PM EST  Analyst Ratings For Merck & Co   Benzinga
11:00AM EST  Merck's COVID-19 Pill works Against Omicron, Lab Studies Show   Benzinga
08:58AM EST  Merck (MRK) and Ridgeback Biotherapeutics reported data from six preclinical studies showing that molnupiravir, an investigational oral antiviral COVID-19 medicine, was active against the Omicron variant in In Vitro studies. The in vitro studies were independently conducted by researchers from institutions in six countries.   RTTNews
08:49AM EST  Merck's Molnupiravir, COVID-19 Medicine, Shows Activity Against Omicron Variant In Vitro Studies   RTTNews
08:38AM EST  JP Morgan Maintains Overweight on Merck & Co, Lowers Price Target to $95   Benzinga
08:21AM EST  The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron   Benzinga
06:48AM EST  Merck And Ridgeback's Molnupiravir, An Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant In Vitro Studies   Benzinga
05:19AM EST  India's Dr. Reddy's Labs Exec Says Have Commenced Commercial Production of Generic Version of Molnupiravir   Benzinga
Jan 27, 2022
10:17AM EST  Jiangsu Recbio Shoots To Become Hong Kong's First HPV Vaccine Stock   Benzinga
09:21AM EST  Merck's Keytruda Wins European Approval For Post-Surgery Kidney Cancer   Benzinga
08:12AM EST  The European Commission has approved Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, KEYTRUDA, as monotherapy for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.   RTTNews
07:58AM EST  The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study   Benzinga
07:50AM EST  Merck: EU Approves KEYTRUDA As Adjuvant Therapy For Certain Patients With Renal Cell Carcinoma   RTTNews
06:53AM EST  Cue Pharma Posts Two Responses From CUE-101 Combo In Head & Neck Cancer   Benzinga
06:52AM EST  European Commission Approves Merck's KEYTRUDA As Adjuvant Therapy For Certain Patients With Renal Cell Carcinoma Following Surgery   Benzinga
Jan 26, 2022
07:42AM EST  Evaxion Biotech Announces Publication Of Clinical Data Of EVX-01 In OncoImmunology Journal   Benzinga
Jan 24, 2022
10:28PM EST  FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why   Benzinga
02:17PM EST  Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments?   Benzinga
07:43AM EST  Merck & Co Inc. (MRK) on Tuesday said the FDA refused to approve its investigational drug, gefapixant for the treatment chronic cough and sought additional information related to the drug's efficacy.   RTTNews
07:20AM EST  Merck: FDA Issues Complete Response Letter For Gefapixant For Refractory Chronic Cough   RTTNews
07:14AM EST  Merck's Gefapixant For Chronic Cough Slapped With FDA Complete Response Letter   Benzinga
06:51AM EST  Merck Provides U.S. And Japan Regulatory Update For Gefapixant   Benzinga
06:48AM EST  Merck Says its Gefapixant for Treatment of Chronic Cough was Approved in Japan   Benzinga
06:47AM EST  Merck Says the FDA Issued a Complete Response Letter for the Company's Gefapixant for the Treatment of Chronic Cough, The FDA is Requesting Additional Information Before Approving the Treatment   Benzinga
Jan 21, 2022
12:12PM EST  Merck Scores Win In Insurance Battle Over Cyberattack - Bloomberg Report   Benzinga
05:11AM EST  Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field   Benzinga
Jan 20, 2022
08:28AM EST  The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug   Benzinga
06:58AM EST  Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial Of KEYTRUDA Plus LENVIMA In Advanced Endometrial Carcinoma Published In The New England Journal of Medicine   Benzinga
Jan 19, 2022
09:31AM EST  Seagen's SEA-CD40 Combo Regime Shows Preliminary Antitumor Activity In Pancreatic Cancer   Benzinga
07:56AM EST  Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory Trial   Benzinga
Jan 18, 2022
05:03PM EST  Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Versus Placebo In Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib   Benzinga
08:05AM EST  Merck Animal Health's Third Veterinarian Wellbeing Study Reveals Increased Health Challenges   RTTNews
08:03AM EST  Merck Animal Health's Third Veterinarian Wellbeing Study Reveals Increased   PR Newswire
07:14AM EST  Merck & Co Inc. (MRK) and Ridgeback Biotherapeutics on Tuesday announced supply agreement with the United Nations Children's Fund (UNICEF) for their investigational antiviral treatment for Covid-19, molnupiravir.   RTTNews
06:56AM EST  Merck, Ridgeback To Supply 3 Mln Doses Of COVID Antiviral Molnupiravir To Unicef In 2022   RTTNews
06:46AM EST  Merck and Ridgeback Announce Supply Agreement With UNICEF For COVID-19 Oral Antiviral Molnupiravir; Merck To Allocate Up To 3M Courses Of Molnupiravir To UNICEF For 1H 2022   Benzinga
05:44AM EST  Canada Approves Pfizer's At-Home COVID-19 Antiviral Treatment, But Deliveries Delayed   Benzinga
Jan 12, 2022
08:30AM EST  The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award   Benzinga
Jan 11, 2022
09:14AM EST  Aligos Therapeutics Expands Collaboration With Merck To Develop Oligonucleotide Therapies For NASH   Benzinga
Jan 10, 2022
11:51AM EST  Merck CEO Says It Will Produce At Least 20M Courses Of COVID Treatment In 2022   Benzinga
11:22AM EST  Merck CEO Now Appearing On CNBC   Benzinga
09:26AM EST  Gilead Sciences, Inc. (GILD) announced Monday that it has entered into two clinical trial collaboration and supply agreements with Merck & Co Inc.(MRK), known as MSD outside the U.S. and Canada.   RTTNews
08:34AM EST  Gilead Announces Clinical Trial Collaborations With Merck To Evaluate Trodelvy In Combination With KEYTRUDA In First-Line Metastatic Non-Small Cell Lung Cancer   Benzinga
08:32AM EST  Merck Announces Phase 3 KEYNOTE-091 Trial Met One Of Its Primary Endpoints Of Disease-Free-survival   Benzinga
08:27AM EST  Neoleukin Therapeutics Announces Clinical Collaboration With Merck To Evaluate NL-201 In Combination With KEYTRUDA   Benzinga
07:19AM EST  Merck's Keytruda As Adjuvant Treatment Improves Disease-Free Survival In Lung Cancer Setting   Benzinga
06:46AM EST  Merck's KEYTRUDA Showed Statistically Significant Improvement In Disease-free Survival Versus Placebo As Adjuvant Treatment For Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless Of PD-L1 Expression   Benzinga
Jan 7, 2022
04:37PM EST  Check Out What Whales Are Doing With MRK   Benzinga
01:01PM EST  Absci Announces Research Collaboration with Merck; Absci Eligible to Receive up to $610M in Upfront Fees and Milestone Payments Plus Royalties   Benzinga
Jan 5, 2022
06:38AM EST  India Health Official Said Merck Covid Drug Has Major Safety Concerns, Not Included in Govt Health Protocol   Benzinga
Jan 4, 2022
01:20PM EST  Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters   Benzinga
08:00AM EST  Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of   GlobeNewswire Inc
Jan 3, 2022
09:13AM EST  The U.S. Food and Drug Administration has granted Fast Track Designation for Genprex Inc.'s (GNPX), lead drug candidate, REQORSA Immunogene Therapy, in combination with Merck & Co's Keytruda in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer or NSCLC whose disease progressed after treatment with Keytruda.   RTTNews
08:03AM EST  Genprex Receives FDA Fast Track Designation For REQORSA Immunogene Therapy In Combination With Keytruda For Treatment Of Non-Small Cell Lung Cancer   Benzinga
06:43AM EST  FDA Approves Another COVID-19 Antiviral Pill, This Time From Merck   Benzinga
Dec 29, 2021
04:49PM EST  Select Walmart And Sam's Club Pharmacies Announce Are Ready To Dispense Authorized COVID-19 Antiviral Medication Through Federal Retail Pharmacy Therapeutics Program   Benzinga
Dec 27, 2021
06:46AM EST  Merck Announces KEYTRUDA Plus LENVIMA Approved In Japan For Patients With Unresectable, Advanced Or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy   Benzinga
Dec 26, 2021
09:53AM EST  The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year   Benzinga
Dec 23, 2021
03:01PM EST  How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?   Benzinga
01:41PM EST  The U.S. Food and Drug Administration on Thursday authorized a second anti-viral pill to treat Covid-19, just a day after authorizing the first antiviral pill for the coronavirus.   RTTNews
11:28AM EST  FDA Official Says Available Data Indicates Merck, Pfizer's COVID Antiviral Pills Are Effective Against Omicron   Benzinga
11:09AM EST  Merck Press Release Confirms Co., Ridgeback's Molnupiravir Receives FDA Emergency Use Authorization For Treatment Of Mild To Moderate COVID   Benzinga
09:41AM EST  FDA Approves Another COVID-19 Antiviral Pill, This Time From Merck   Benzinga
09:39AM EST  'FDA grants [emergency use authorization] to second #covid19 antiviral pill, from Merck/Ridgeback' -Tweet From CNBC Pharma Report Meg Tirrell   Benzinga
09:23AM EST  FDA Authorizes Additional Oral Antiviral For Treatment Of COVID-19 In Certain Adults   Benzinga
Dec 22, 2021
05:39PM EST  'White House warns Pfizer Covid-19 pill will not be widely available for months' -Recent FT Article   Benzinga
03:46PM EST  White House Covid-19 Response Coordinator Zients Says Anti-viral Treatments Will Be Provided to States, Localities at No Charge   Benzinga
03:26PM EST  'In @WHCOVIDResponse briefing, Zients gives update on supply in what he calls the nation's medicine cabinet for #covid19. In Jan.: 265K courses of Pfizer drug, 3M of Merck drug (if authorized), 500K+ of AZN preventive antibody, 300K of Vir/GSK antibody'   Benzinga
12:49PM EST  White House Says Has Purchased 10M Doses Of Antiviral COVID Pill From Pfizer, 3M Doses From Merck   Benzinga
10:05AM EST  A Look Into Merck & Co's Debt   Benzinga
09:18AM EST  FDA To Possibly Authorize Pfizer, Merck COVID-19 Antiviral Pills This Week: Bloomberg   Benzinga
09:16AM EST  UK Calls For Additional Doses Of COVID-19 Antivirals From Merck, Pfizer   Benzinga
07:42AM EST  The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda   Benzinga
06:57AM EST  Merck, Ridgeback Say British Govt. Agrees To Procure   RTTNews
06:17AM EST  Merck And Ridgeback Announce U.K. Government To Buy Addl 1.75 Mln Doses Of Molnupiravir   RTTNews
06:01AM EST  Merck and Ridgeback Announce UK Government To Purchase Additional 1.75M Courses Of Molnupiravir   Benzinga
Dec 21, 2021
07:06AM EST  IMV Announced Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts   Benzinga
Dec 17, 2021
09:54AM EST  EMA's CHMP Backs Approval For Merck's Keytruda In Adjuvant Setting For Kidney Cancer   Benzinga
09:53AM EST  EMA Might Not Decide On Merck's COVID-91 Oral Antiviral Before Christmas: Reuters   Benzinga
07:54AM EST  The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx   Benzinga
07:11AM EST  Merck: CHMP Adopts Positive Opinion For KEYTRUDA As   RTTNews
06:59AM EST  Merck Gets Positive EU CHMP Opinion For KEYTRUDA As Adjuvant Therapy For Renal Cell Carcinoma   RTTNews
06:45AM EST  Merck Reports Positive European Union Committee For Medicinal Products For Human Use For KEYTRUDA   Benzinga
06:24AM EST  Hearing Goldman Added Merck To Its 'Conviction Buy' List   Benzinga
Dec 16, 2021
05:20PM EST  Merck, Ridgeback Biotherapeutics Highlights 'New England Journal Of Medicine' Published Findings From Phase 3 MOVe-OUT Trial Evaluating Molnupiravir In Non-Hospitalized High Risk Adults With Mild To Moderate COVID 19   Benzinga
10:14AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021   Benzinga
06:35AM EST  Daiwa Capital Initiates Coverage On Merck & Co with Neutral Rating, Announces Price Target of $70   Benzinga
Dec 15, 2021
08:03AM EST  The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO   Benzinga
Dec 14, 2021
01:26PM EST  Merck, P&G Among Partners Launching Research To Int'l. Space Station Via SpaceX CRS-24   Benzinga
Dec 13, 2021
05:09PM EST  UPDATE: Merck Press Release Confirms Clinical Holds On Studies Evaluating Islatravir   Benzinga
10:48AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2021   Benzinga
08:50AM EST  Merck Raises $1 Billion Via Inaugural Sustainability Bond   Benzinga
08:10AM EST  UBS Downgrades Merck & Co to Neutral, Lowers Price Target to $76   Benzinga
Dec 9, 2021
09:50PM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021   Benzinga
09:47PM EST  Wells Fargo Initiates Coverage On Merck & Co with Overweight Rating, Announces Price Target of $90   Benzinga
Dec 8, 2021
01:10PM EST  Merck & Co Whale Trades Spotted   Benzinga
09:03AM EST  Sotio Announces Clinical Collaboration With MSD To Evaluate Il-15 Superagonist, SOT101, In Combination With Keytruda In Patients With Solid Tumors; Phase 2 Aurelio-04 Study Will Be Conducted In Us And Selected European Countries And Will Begin In 1H 2022   Benzinga
08:19AM EST  The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom   Benzinga
Dec 7, 2021
12:49PM EST  Pfizer, Merck COVID-19 Pills US Launch In This Month; Other Countries Will Have to Wait: WSJ   Benzinga
11:06AM EST  Where Merck & Co Stands With Analysts   Benzinga
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021   Benzinga
08:26AM EST  The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Dar   Benzinga
07:43AM EST  Guggenheim Downgrades Merck & Co to Neutral   Benzinga
07:24AM EST  Merck Announces Addl $150 Mln Investment Through 2025 To Help End Maternal Mortality Inequities   RTTNews
06:06AM EST  Merck Stops Enrollment In Two Islatravir Trials For Prevention Of HIV Infection   Benzinga
Dec 6, 2021
05:01PM EST  Merck Reports Pause Of Enrollment In 2 Phase 3 Trials Of Its Oral Islatravir For Pre-Exposure Prophylaxis Of HIV-1 Infection   Benzinga
10:52AM EST  Merck Canada Announces Expansion of Manufacturing for Molnupiravir, an   PR Newswire
10:52AM EST  Merck Canada Announces Expansion Of Manufacturing For Molnupiravir, An Investigational Oral Antiviral Medicine For Treatment of COVID-19   Benzinga
08:54AM EST  Benzinga Pro's Top 5 Stocks To Watch For Monday, Dec. 6, 2021: MRK, COIN, BZFD, XSPA, RETA   Benzinga
08:04AM EST  Canada, Merck Ink Supply Pact For 1M Doses Of Molnupiravir For COVID-19   Benzinga
08:04AM EST  IO Biotech Announces Third Clinical Collaboration With Merck To Evaluate IO102-IO103 In Combination With KEYTRUDA As First-Line Treatment In A Phase 2 Multi-Arm Basket Trial   Benzinga
07:59AM EST  Merck's Keytruda Wins Eighth FDA Approval Of 2021, This Time For Adjuvant, Pediatric Melanoma Settings   Benzinga
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Dec 3, 2021
02:09PM EST  Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19, with the Government of Canada   PR Newswire
01:26PM EST  Canada Signs Deal With Merck For 500K Doses Of COVID-19 Oral Antiviral Treatment, Pending Health Canada Approval   Benzinga
11:05AM EST  Bristol Myers - Merck's Thalassemia Candidate Under FDA Priority Review   Benzinga
07:40AM EST  The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering   Benzinga
Dec 2, 2021
12:02PM EST  Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates   Benzinga
Dec 1, 2021
04:31PM EST  FDA Panel Narrowly Recommends Use Of Merck's Covid-19 Pill   RTTNews
08:41AM EST  The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case   Benzinga
08:38AM EST  Merck's Pneumococcal 15-valent Conjugate Vaccine Under Priority FDA Review For Use In Kids   Benzinga
08:36AM EST  The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment, Regulatory Setbacks For CTI Biopharma, Favorable Ruling For BioXcel, Viatris In Tecfidera Patent Case   Benzinga
06:49AM EST  Merck Announces FDA Accepts For Priority Review Supplemental Biologics License Application For Merck's VAXNEUVANCE For Use In Infants And Children   Benzinga
Nov 30, 2021
05:09PM EST  FDA Could Authorize Merck-Ridgeback COVID-19 Pill Next Month   Benzinga
05:07PM EST  Merck Shares Spike Higher; FDA Advisers Vote To Recommend Authorization Of Co's Oral Pill For Treatment Of Mild-To-Moderate COVID-19 In Adults At High Risk Of Progressing To Disease   Benzinga
04:47PM EST  The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout   Benzinga
04:44PM EST  AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting   Benzinga
04:42PM EST  AstraZeneca And Merck Announce FDA Has Accepted Submission Of Supplemental New Drug Application For LYNPARZA   Benzinga
04:42PM EST  Merck's KEYTRUDA Approved In Japan In Combination With Chemotherapy For First-Line Treatment Of Patients With Radically Unresectable, Advanced Or Recurrent Esophageal Carcinoma   Benzinga
04:03PM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021   Benzinga
04:02PM EST  Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma   Benzinga
02:07PM EST  FDA To Decide On Merck's Covid-19 Pill   RTTNews
Nov 29, 2021
03:51PM EST  New Jersey-based healthcare company, Merck & Co., Inc. (MRK) saw its stock drop 6% after analysts downgrade the stock to "Neutral" from "Buy". The news came after the company published the data from its large-scale trial of Covid pills. The results showed a lower efficacy rate of the pills than was expected. This lead to Citi analysts downgrading the stock.   RTTNews
08:22AM EST  Morgan Stanley Maintains Equal-Weight on Merck & Co, Lowers Price Target to $82   Benzinga
07:36AM EST  Merck : EU Approves KEYTRUDA Plus LENVIMA For Certain   RTTNews
07:29AM EST  10 Biggest Price Target Changes For Monday   Benzinga
07:17AM EST  Merck: EU Approves KEYTRUDA + LENVIMA As 1st-Line Treatment For Advanced Renal Cell Carcinoma   RTTNews
07:15AM EST  Merck: EU Approves KEYTRUDA+ LENVIMA For Patients With Certain Types Of Endometrial Carcinoma   RTTNews
06:46AM EST  Merck Announces European Commission Approves KEYTRUDA Plus LENVIMA As First-Line Treatment For Adult Patients With Advanced Renal Cell Carcinoma   Benzinga
06:12AM EST  Citigroup Downgrades Merck & Co to Neutral, Lowers Price Target to $85   Benzinga
Nov 28, 2021
09:43AM EST  The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week   Benzinga
Nov 26, 2021
07:17AM EST  Merck (MRK) and Ridgeback Biotherapeutics issued an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine for COVID-19. In the study, Molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group to 6.8% in the molnupiravir group. Nine deaths were reported in the placebo group, and one in the molnupiravir group.   RTTNews
06:51AM EST  Merck And Ridgeback Biotherapeutics Provide Update On Results From MOVe-OUT Study Of Molnupiravir   RTTNews
06:47AM EST  UPDATE: Merck Says 'Nine deaths were reported in the placebo group, and one in the molnupiravir group.'   Benzinga
06:46AM EST  Merck And Ridgeback Biotherapeutics Provide Update On Results From MOVe-OUT Study Of Molnupiravir; Molnupiravir Reduced Risk Of Hospitalization Or Death From 9.7% In Placebo Group To 6.8% In Molnupiravir Group   Benzinga
Nov 24, 2021
09:33AM EST  Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial   Benzinga
Nov 23, 2021
11:04AM EST  Merck Says Health Canada Approves KEYTRUDA In Combination With Chemotherapy For Treatment Of Locally Recurrent Unresectable Or Metastatic Triple-Negative Breast Cancer   Benzinga
11:02AM EST  Chemotherapy for the Treatment of Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS 10)   PR Newswire
07:17AM EST  Novartis May Have Buyer(s) For Its Sandoz Unit - Report   Benzinga
Nov 19, 2021
11:55AM EST  Where Merck & Co Stands With Analysts   Benzinga
10:09AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021   Benzinga
08:20AM EST  The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial   Benzinga
07:43AM EST  Merck Pauses Development Of MK-8507 In HIV Infection   Benzinga
05:28AM EST  BMO Capital Initiates Coverage On Merck & Co with Market Perform Rating, Announces Price Target of $91   Benzinga
Nov 18, 2021
05:59PM EST  UPDATE: Merck Says 'remains confident in islatravir's overall profile and is continuing with development of islatravir across a range of settings including in treatment of patients living with HIV and in pre-exposure prophylaxis'   Benzinga
05:59PM EST  UPDATE: Merck Says Auto Recommendation Of External Data Monitoring Committee, Co. Will Stop Dosing In Trial   Benzinga
05:58PM EST  UPDATE: Merck Says Review By External Data Monitoring Committee Determined Effect Of Decreases In Lymphocyte Was Related To Treatment With Combo   Benzinga
05:58PM EST  UPDATE: Merck Says 'Decreases in total lymphocyte and CD4+ T-cell counts were observed in study participants randomized to receive ISL+MK-8507'   Benzinga
05:57PM EST  Merck Offers Update On Phase 2 Trial Of Once-Weekly Investigational Combo Of MK-8507, Islatravir For Treatment Of HIV-1   Benzinga
02:33PM EST  India's Government Has No Plans Yet To Buy Merk's COVID Pills; Approves 20M Novavax Vaccine Dose Order   Benzinga
09:53AM EST  Merck's Keytruda Scores First Approval In Adjuvant Kidney Cancer Setting   Benzinga
07:55AM EST  Berkshire Exited Merck Before COVID Pill Boost; Trimmed Holdings In AbbVie, Bristol Myers In Q3   Benzinga
06:46AM EST  FDA Approves Merck's KEYTRUDA As Adjuvant Therapy For Certain Patients With Renal Cell Carcinoma Following Surgery   Benzinga
Nov 17, 2021
10:30AM EST  Merck Shares Quiet; The Hill Reports 'Lab worker finds vials labeled 'smallpox' at Merck facility'   Benzinga
09:48AM EST  FDA Plans Quick Review of Pfizer/BioNTech COVID-19 Booster For All Adults: NYT   Benzinga
06:46AM EST  Merck Announces Expiration Of Hart-Scott-Rodino Act Waiting Period And Extension Of Tender Offer To Acquire Acceleron Pharma Inc.   Benzinga
06:09AM EST  Merck and Ridgeback To Present Phase 3 Data For Molnupiravir At American Society Of Tropical Medicine And Hygiene (ASTMH) 2021 Annual Meeting   Benzinga
01:05AM EST  -- New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. -- Avelumab (BAVENCIO) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or gastroesophageal junction adenocarcinomas (neoHERIZON) -- neoHERIZON will assess HER-Vaxx in combination with chemotherapy with or without avelumab in HER-2 positive gastric cancer   GlobeNewswire Inc
Nov 16, 2021
08:07AM EST  Dr. Reddy's Ready To Make COVID-19 Antiviral From Pfizer - Reuters   Benzinga
Nov 11, 2021
02:22PM EST  Oncorus, Gaeta Therapeutics Ink Cancer Candidate Licensing Agreement   Benzinga
08:49AM EST  Merck Initiates Phase 3 Study Of VERQUVO In Chronic Heart   RTTNews
08:39AM EST  Merck Begins Phase 3 Study Of VERQUVO In Chronic Heart Failure And Reduced Ejection Fraction   RTTNews
08:03AM EST  The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts   Benzinga
06:47AM EST  Merck Announces Initiation Of Phase 3 Study Evaluating VERQUVO In Patients With Chronic Heart Failure And Reduced Ejection Fraction Who Have Not Had A Recent Worsening Heart Failure Event   Benzinga
Nov 10, 2021
08:23AM EST  The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance   Benzinga
08:10AM EST  Merck, Ridgeback Announce Japanese Government To Purchase 1.6M Courses Of Molnupiravir Upon Authorization Or Approval   Benzinga
Nov 9, 2021
11:46AM EST  US Government To Purchase Additional 1.4M Doses Of Merck's COVID-19 Pill   Benzinga
11:42AM EST  The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data   Benzinga
11:28AM EST  Merck and Ridgeback Announce U.S. Government To Purchase 1.4M Additional Courses Of Molnupiravir, An Investigational Oral Antiviral Medicine, For Treatment Of Mild-To-Moderate COVID-19 For ~$1B   Benzinga
11:08AM EST  Merck Reports Pending Acquisition Of Acceleron Pharma Cleared By Competition Authorities In Germany, Austria   Benzinga
10:49AM EST  Merck Ahead Of Pfizer In Talks With Europe For COVID-19 Pills: Reuters   Benzinga
06:53AM EST  Biopharmaceutical major Merck & Co., Inc. (MRK) and Florida-based Ridgeback Biotherapeutics announced Tuesday that the U. S. government will purchase a total of 1.4 million additional courses of molnupiravir, if authorized, for approximately $1 billion.   RTTNews
06:30AM EST  Merck And Ridgeback: U.S. Government To Purchase 1.4 Mln Addl Courses Of Molnupiravir ForCOVID-19   RTTNews
Nov 8, 2021
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
Nov 5, 2021
05:26PM EDT  Will Pfizer Outgun Merck With Oral COVID-19 Pill?   Benzinga
03:26PM EDT  White House Says It Is Preparing To Secure Both Merck, Pfizer COVID-19 Pills   Benzinga
Nov 4, 2021
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
06:41AM EDT  Merck Confirms Earlier Report Co And Ridgeback's Molnupiravir Oral COVID-19 Antiviral Approved In U.K.   Benzinga
06:36AM EDT  'Britain authorizes Merck's covid-19 treatment pill molnupiravir, in the world's first approval of drug' -Washington Post Report   Benzinga
Nov 2, 2021
10:27AM EDT  Merck Pushes Acceleron Buyout By Refiling For Antitrust Review   Benzinga
Nov 1, 2021
12:42PM EDT  Merck Dives Further Into Cytokine Research With Synthekine Deal   Benzinga
12:21PM EDT  Analyst Ratings For Merck & Co   Benzinga
10:05AM EDT  Barclays Maintains Overweight on Merck & Co, Raises Price Target to $94   Benzinga
08:40AM EDT  Argus Research Upgrades Merck & Co to Buy, Announces $110 Price Target   Benzinga
07:27AM EDT  New Data Reaffirms Merck's Keytruda In Extending Survival In Melanoma Patients   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 29, 2021
12:14PM EDT  Expert Ratings For Merck & Co   Benzinga
10:14AM EDT  Morgan Stanley Maintains Equal-Weight on Merck & Co, Raises Price Target to $90   Benzinga
08:00AM EDT  The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs   Benzinga
Oct 28, 2021
04:10PM EDT  Gilead Reports Trial Collab With Merck To Evaluate Trodelvy In Combo With KEYTRUDA In Patients with First-Line Metastatic Triple-Negative Breast Cancer   Benzinga
03:49PM EDT  Cheap Antidepressant Fluvoxamine Shows Potential In Reducing COVID-19 Hospitalization   Benzinga
11:42AM EDT  Why Merck Shares Are Making New 52-Week Highs Today   Benzinga
08:27AM EDT  Merck Sees Sales Of $5B-$7B From COVID-19 Drug In 2022   Benzinga
08:27AM EDT  Merck Sees $500M-$1B Of Revenue From COVID-19 Antiviral Drug This Year   Benzinga
08:26AM EDT  The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug   Benzinga
07:14AM EDT  Recap: Merck & Co Q3 Earnings   Benzinga
07:07AM EDT  Biopharmaceutical company Merck & Co., Inc. (MRK) reported Thursday that third-quarter net income attributable to the company increased to $4.57 billion or $1.80 per share from $2.32 billion or $0.92 per share in the prior-year quarter.   RTTNews
06:55AM EDT  Merck & Co Inc. (MRK) announced a profit for its third quarter that increased from last year.   RTTNews
06:34AM EDT  Merck Q3 GAAP EPS From Cont Opns $1.80; Non-GAAP EPS From Cont Opns $1.75   RTTNews
06:33AM EDT  Merck Sees FY21 Adj. EPS $5.65-$5.70 Vs. $5.77 Est., Sales $47.4B-$47.9B Vs. $48.16B   Benzinga
06:31AM EDT  Merck & Co Q3 EPS $1.75 Beats $1.55 Estimate, Sales $13.20B Beat $12.33B Estimate   Benzinga
06:02AM EDT  A Peek Into The Markets: US Stock Futures Edge Higher; Apple, Amazon Earnings In Focus   Benzinga
04:08AM EDT  Earnings Scheduled For October 28, 2021   Benzinga
Oct 27, 2021
10:24AM EDT  Earnings Preview For Merck & Co   Benzinga
09:05AM EDT  Merck & Co., Inc. (MRK) said Wednesday that it has signed a voluntary licensing deal with the UN-backed Medicines Patent Pool to facilitate affordable global access for molnupiravir, an investigational oral COVID-19 antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.   RTTNews
08:40AM EDT  Merck Inks Licensing Pact To Broaden Generic Manufacturing Of COVID-19 Antiviral   Benzinga
08:39AM EDT  Merck Signs Deal For COVID-19 Medicine To Increase Broad Access In Low- & Middle-Income Countries   RTTNews
06:47AM EDT  Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021   Benzinga
06:11AM EDT  The Medicines Patent Pool (MPP) and Merck AnnounceLicense Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries   Benzinga
Oct 26, 2021
08:36AM EDT  The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children   Benzinga
06:49AM EDT  Gilead, Merck Begin Phase 2 Study Evaluating Lenacapavir With Islatravir For HIV-1 In Virologically Suppressed Adults   RTTNews
06:48AM EDT  Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults   Benzinga
Oct 25, 2021
08:17AM EDT  Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Monday a collaboration agreement with Merck & Co., Inc. (MRK), with an option to license Xeris' suspension-based formulation technology, XeriJect, for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulations.   RTTNews
08:02AM EDT  Merck Announces Initiation Of Rolling Review By EMA For   RTTNews
07:54AM EDT  Merck & Co., Inc. (MRK) announced positive results from two pivotal Phase 3 trials of the investigational, once-daily oral fixed dose combination pill of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection who are virologically suppressed on different antiretroviral therapy regimens or bictegravir/emtricitabine/tenofovir.   RTTNews
07:44AM EDT  Xeris Pharmaceuticals Enters Collaboration Agreement With Merck; Financial Terms Not Disclosed   Benzinga
07:30AM EDT  Merck Says Phase 3 Trials Fixed Dose Combination Of Doravirine/Islatravir For HIV-1 Infection Meets Primary Endpoint   RTTNews
06:46AM EDT  Merck Announces Top-Line Results From Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination Of Doravirine/Islatravir For Treatment Of People With HIV-1 Infection; Week 48 Data Met Safety And Efficacy Endpoints   Benzinga
06:09AM EDT  Evaxion Biotech Announces Clinical Collaboration With Merck To Evaluate Lead Product Candidate With KEYTRUDA (pembrolizumab) In Patients With Melanoma   Benzinga
06:08AM EDT  Merck And Ridgeback Announce Initiation Of A Rolling Review By European Medicines Agency For Molnupiravir, An Investigational Oral Antiviral Medicine, For The Treatment Of COVID-19 In Adults   Benzinga
05:52AM EDT  Evaxion Biotech A/S (EVAX) has entered into a clinical trial collaboration and supply agreement with subsidiaries of Merck & Co. to evaluate the combination of Evaxion's cancer immunotherapy EVX-01 with MSD's KEYTRUDA in a new phase 2b study. Evaxion will be responsible for the conduct of the study.   RTTNews
Oct 24, 2021
11:45AM EDT  The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More   Benzinga
Oct 22, 2021
04:26PM EDT  A-List Executive Team, Big-Name Backers Fail to Lift Abbisko IPO   Benzinga
12:20PM EDT  Where Merck & Co Stands With Analysts   Benzinga
07:48AM EDT  EU Approves Merck's Keytruda Plus Chemotherapy To Treat   RTTNews
07:36AM EDT  The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs   Benzinga
07:25AM EDT  Merck: European Commission Approves KEYTRUDA + Chemotherapy For Triple-negative Breast Cancer   RTTNews
06:46AM EDT  Merck Reports European Commission Approves Co.'s KEYTRUDA Plus Chemo As Treatment For Certain Patients With Locally Recurrent Unresectable Or Metastatic Triple-Negative Breast Cancer   Benzinga
06:33AM EDT  SVB Leerink Maintains Outperform on Merck & Co, Raises Price Target to $105   Benzinga
Oct 21, 2021
01:11PM EDT  Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg   Benzinga
12:11PM EDT  The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO   Benzinga
12:11PM EDT  CDC's Advisory Committee Backs Pneumococcal Vaccine From Pfizer, Merck   Benzinga
12:11PM EDT  Bloomberg Reported Late Wednesday Bristol-myers Squibb Plans to Tender Its Shares in Acceleron Pharma Following Merck Agreement to Acquire the Biotech Company   Benzinga
10:44AM EDT  Merck & Co., Inc., known as MSD outside the U.S. and Canada, has recalled one lot of intravenous antibiotic Cubicin (daptomycin for injection) 500 mg for the potential presence of particulate matter identified as glass particles, the U.S. Food and Drug Administration or FDA said in a statement.   RTTNews
Oct 20, 2021
08:16AM EDT  The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review   Benzinga
08:07AM EDT  Acceleron Pharma Shareholder Darwin Global Urges Co. Shareholders Not To Tender Shares To Merck   Benzinga
06:26AM EDT  Merck Recalls One Lot Of Cubicin Antibiotic Over Glass Particles Presence In Vials   Benzinga
Oct 19, 2021
03:00PM EDT  Psychedelics Discussed At Benzinga Cannabis Capital Conference: Growth Opportunities, Mental Health & Pharma   Benzinga
08:33AM EDT  David v Goliath in The Race to Develop an Oral Therapy for COVID-19   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC